Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
To our knowledge BAY has not progressed
2024-12-30

To our knowledge, BAY 60-6583 has not progressed to clinical development and remains to be the only ADORA2B agonist that has been developed.33, 34 Further development of similar compounds would be beneficial in future fibrosis research. One of the limitations of our study is being limited to in vit
-
By applying each external load to
2024-12-30

By applying each external load to the G-actin molecule, and measuring the elongation of the molecule, we computed force-displacement curves. The force versus displacement curve can be used to evaluate the tensile stiffness of the G-actin from a linear regression analysis. Followed by statistical ana
-
Fenofibrate Luciferase Immunoprecipitation Systems LIPS whic
2024-12-30

Luciferase Immunoprecipitation Systems (LIPS), which utilizes recombinant antigens fused to the enzyme reporter Renilla luciferase (Ruc) to detect patient antibodies, provides a unique platform to investigate Fenofibrate directed against a variety of antigenic targets [25]. Previously, LIPS has been
-
br Acknowledgements br Introduction Autoantibodies directed
2024-12-30

Acknowledgements Introduction Autoantibodies directed at neurotransmitter receptors and ion channels are pathogenic and/or biomarkers in several autoimmune neurological diseases [1]. For example, autoantibodies directed against voltage-gated potassium channels, the P/Q-type (α1A) voltage-gated
-
Recently biosensors based on enzyme mimicking organic
2024-12-30

Recently, biosensors based on enzyme-mimicking organic-inorganic hybrid nanomaterials such as protein or DNA-Cu nanoflowers (Batule et al., 2015, Park et al., 2017), Fe-aminoclay (Lee et al., 2013), and MOFs (Ai et al., 2013, Dong et al., 2015, Feng et al., 2012, Liu et al., 2013, Qin et al., 2013,
-
In pancreatic islets we found an increase in protein
2024-12-27

In pancreatic islets we found an increase in protein expression of leukocyte 12/15-LO that paralleled the metabolic decline characterized by severe hyperglycemia and reduced islet numbers. Similar increase in 12/15-LO expression by Western blot was found in the control mice, which have a normal meta
-
NOS is classified into three
2024-12-27

NOS is classified into three isoforms: endothelial (eNOS), neuronal (nNOS), and inducible (iNOS), iNOS is expressed in macrophages (Eisenstein, Huang, Meissler Jr, & al-Ramadi, 1994) and osteoblast-like cells (Riancho et al., 1995) and is involved in the regulation of inflammatory reactions (Eisenst
-
Assessment of antibiotic appropriateness is receiving increa
2024-12-27

Assessment of antibiotic appropriateness is receiving increased attention in the face of growing concerns about the emergence of MDROs, as well as the rise in adverse outcomes associated with antibiotic use such as C. difficile infection. In this study, 15% of cultured Gram-negative organisms met th
-
Aconitase clusters are prone to oxidations and
2024-12-27

Aconitase clusters are prone to oxidations and are among the first to undergo a change in transition state during stages of electrophilic stress rendering them inactive [31]. Aconitase activity in LETO and OLETF did not differ at T0 suggesting that the early onset of insulin resistance may not be a
-
Moreover a multiple regression analysis using
2024-12-27

Moreover, a multiple regression analysis using the 1-year MMSE score as a dependent variable was conducted. The result showed that serum ConA beads for glycosylation studies levels at admission did not affect the MMSE score 1 year later (β = 0.10, p = 0.639). Discussion In this study, serum Aβ4
-
br Conflict of interest statement br Introduction Tanshinone
2024-12-27

Conflict of interest statement Introduction Tanshinone IIA (Tan IIA) is a major active component of Salvia miltiorrhiza (S. miltiorrhiza), a well-known Chinese traditional medicine that is used for the treatment of cardiovascular and cerebrovascular diseases [1]. Tan IIA exhibits diverse pharm
-
br Alzheimer s disease AD is an irreversible age
2024-12-27

Alzheimer’s disease (AD) is an irreversible, age-associated neurodegenerative disorder that is characterized by progressive memory loss and cognitive decline. AD is also the leading cause of dementia, accounting for 5 million cases in the United States and 44 million cases worldwide. In 2015, AD c
-
Tephrosia purpurea Linn pers Fabaceae
2024-12-27

Tephrosia purpurea (Linn.) pers, (Fabaceae), a widely growing herbaceous perennial is reported to exhibit significant anti-hyperglycemic activity in animal models [7], [8], [9] as well as able to delay the development of diabetic complications [10], [11]. Recently, we have reported T. purpurea for i
-
The synthetic route to M developed by Rice was utilized
2024-12-26

The synthetic route to M100907 developed by Rice was utilized, however, the chiral resolution was carried out at an earlier stage to provide the possibility of introducing different substituents onto the piperidinyl group. The conditions for this resolution were different from previously reported.
-
The use of a single well identified molecule to
2024-12-26

The use of a single well-identified molecule to induce AChR clusters formation can simplify complicated cell manipulation procedures and may provide a more efficient means of developing biological substitutes for functional muscle tissue restoration in vivo. Pharmacological approaches dealing with b
15856 records 62/1058 page Previous Next First page 上5页 6162636465 下5页 Last page